SGT-001 is under clinical development by Solid Biosciences and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SGT-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGT-001 overview
SGT-001 is under development for the treatment of Duchenne muscular dystrophy (DMD) in adolescents and children. It is administered intravenously in the form of suspension. It is an adeno-associated virus (AAV9) vector-mediated microdystrophin gene therapy that enables the systemic delivery of a synthetic, functional version of the dystrophin gene.
See Also:
For a complete picture of SGT-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.